Qué debe saber el médico de primaria sobre los nuevos marcadores en el cáncer de próstata

TL;DR: The sensitivity in the detection of significant prostate cancer with low prostate-specific antigen should be improved in an attempt to reduce the risk of over-treatment and prognostic biomarkers with genomic tests will help to choose the best therapeutic option for the patient.

Abstract: The use of prostate-specific antigen as a diagnostic tool in the screening of prostate cancer is reflected in an increase in the incidence, an increase in diagnosis at initial stages, and an increase in radical therapies, even at the expense of over-treatment in some cases. It is known from the data collected in the literature that not every patient with high prostate-specific antigen needs a biopsy, and that not every patient diagnosed with prostate cancer needs treatment. With the new emerging prostate markers, we will try to improve the specificity of prostate-specific antigen in the grey area (4-10 ng/ml) should be improved. This should avoid unnecessary biopsies. The sensitivity in the detection of significant prostate cancer with low prostate-specific antigen should also be improved in an attempt to reduce the risk of over-treatment. On the other hand, prognostic biomarkers with genomic tests will help to choose the best therapeutic option for the patient.